Search

everythinglearnresearchcommunity

for

Search:↓

Many users report negative experiences with Dutasteride, claiming it doesn't work as effectively as Finasteride for hair loss, despite some defending its efficacy. The conversation highlights skepticism about Dutasteride's effectiveness, with some users experiencing continued hair loss or no regrowth, while others see positive results.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.

The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.

A user's experience with hair loss treatments, including finasteride and other options such as RU58841, Nizoral, Pumpkin Seed, and Adenosine; the importance of being in a positive frame of mind when considering taking finasteride; and the need to address life issues before starting finasteride.

The user experienced side effects from finasteride and found improved mood and performance with DHT, but it worsened hair loss. They are considering options like TRT, HCG, and topical treatments like Saw Palmetto, but struggle with balancing hair preservation and functionality.

A 22-year-old male experienced hair loss potentially linked to escitalopram, which stopped after switching to vortioxetine. His depressive symptoms improved with continued treatment.

The conversation discusses the theory that finasteride-induced erectile dysfunction (ED) is related to blood flow rather than hormonal changes. The user suggests that lowering LDL cholesterol aggressively might improve ED symptoms for those on finasteride.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

User visited derma doctor, suggested finasteride, minoxidil, multivitamins, and PRP therapy. Another user advised against PRP due to cost and ineffectiveness.

The user plans to switch from topical to oral finasteride (1mg/day) and minoxidil (3mg/day) due to unsatisfactory results with topical treatments. They seek advice on the effectiveness, potential side effects, and the timing for considering a hair transplant, with recommendations to monitor health metrics like blood pressure and conduct thorough bloodwork before starting.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

A 30-year-old with a family history of receding hairlines is considering starting finasteride due to gradual hairline recession. They are seeking advice on whether to begin treatment or if they are worrying unnecessarily.

The user is experiencing headaches and dizziness two weeks after starting finasteride at 1.25mg, concerned about potential brain fog affecting math studies. They mention hearing that headaches can be normal after starting finasteride.

Dutasteride effectively reduces DHT levels and significantly increases testosterone levels. Users are cautious about adding oral minoxidil due to potential heart issues and are considering dosage adjustments with medical guidance.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The user is experiencing hair loss without a family history and suspects stress or telogen effluvium (TE) as the cause, despite using finasteride without results. Others suggest stress, vitamin deficiencies, or other conditions could be factors, and some mention that balding can occur without a family history.

The user reported high estradiol levels after one month of using finasteride for hair loss. They discussed potential side effects and adjustments to their treatment plan.

Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.

A user is considering trying Aevin hair creme, which contains ingredients like jojoba oil and saw palmetto, despite skepticism about its effectiveness compared to treatments like finasteride, minoxidil, or hair transplants. They are wary of the product's legitimacy due to the lack of reviews outside the brand's website.

A user's experience with hair loss treatments, specifically finasteride/dutasteride, and the potential for nocebo effects to influence side-effects. They caution others against focusing too much on possible side-effects when using these drugs, as they are generally safe and effective.